据介绍，高新区持续推动科技创新与产业创新融合发展。 加速科技创新成果产业化。高新区重点面向新一代信息技术、医药健康、量子信息等前沿领域布局3家概念验证中心，强化早期技术的可行性评估与原型 开发，面向新一代信息技术、生物医药、高端装备、新能源新材料等4大领域布局8家科技成果转化中试示范基地，推进国产高端服务器、高性能通用控制 器等技术加快产业化应用，建立"概念验证—中试孵化—产业化"全链条成果转化机制。未来，高新区还将积极谋划在空天信息、基因与生物技术等新领域 布局成果转化平台，加大培育新质生产力。 齐鲁晚报.齐鲁壹点王贝艺 9月4日，济南市召开"深入实施工业强市发展战略"主题系列新闻发布会——高新区专场。 大力支持创新创业。高新区以建设区域性科创高地为目标，推动创新链、产业链、资金链、人才链深度融合；高标准建设中科院济南科创城、国家实验室 济南基地，加快各类科研项目落地转化，力争2025年新认定市级以上高能级创新平台不少于15家；优化齐鲁软件园、创服中心等园区服务功能，完善集成 电路等产业公共服务平台，为企业提供一站式服务；落实市场准入创新举措和研发补助等优惠政策，营造鼓励创新、宽容失败的创业氛围。 ...

关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600056 证券简称：中国医药 公告编号：临 2025-074 号 中国医药健康产业股份有限公司 （网址：https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 2025 年 9 月 4 日（星期四）至 9 月 10 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 meheco600056@meheco.gt.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 中国医药健康产业股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 11 日（星期四） 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务 ...

《关于深入实施"人工智能+"行动的意见》（以下简称《意见》）发布后，上海等地迅速响 应。 9月2日，上海方面发布文件称，为贯彻落实《意见》，统筹布局"人工智能+"6大重点行动 和8大基础支撑能力，加快建设人工智能"上海高地"， 决定开展2025年度上海市"人工智 能+"行动项目申报工作。 据了解，《意见》聚焦行业应用需求和基础能力供给协同推进，开展"人工智能+"科学技术、 产业发展、消费提质、民生福祉、安全治理、全球合作等6大行动，并围绕模型、数据、算 力、应用、开源、人才、政策法规、安全等8个方面，旨在系统构建人工智能基础支撑体系， 推动人工智能与经济社会各领域各行业广泛深度融合，探索形成中国特色人工智能发展路径。 21世纪经济报道记者注意到， 2024年，"人工智能+"首次被写入政府工作报告。 今年政府工 作报告又提出，持续推进"人工智能+"行动。中央持续部署下，全国多地关于"人工智能+"的行 动方案接连出炉， 今年以来，天津、安徽、四川、辽宁、宁夏等多地便规划了关于"人工智能 +"的最新"行动路线"。 此外，北京、浙江、上海、广西、山东、甘肃等多个省（自治区、直 辖市）专门针对重点行业领域进行了"人工智 ...

（原标题："人工智能+"地方路线图陆续出炉 制造、教育、医疗率先部署） 21世纪经济报道见习记者冉黎黎 北京报道 《关于深入实施"人工智能+"行动的意见》（以下简称《意见》）发布后，上海等地迅速响应。9月2 日，上海方面发布文件称，为贯彻落实《意见》，统筹布局"人工智能+"6大重点行动和8大基础支撑能 力，加快建设人工智能"上海高地"，决定开展2025年度上海市"人工智能+"行动项目申报工作。 据了解，《意见》聚焦行业应用需求和基础能力供给协同推进，开展"人工智能+"科学技术、产业发 展、消费提质、民生福祉、安全治理、全球合作等6大行动，并围绕模型、数据、算力、应用、开源、 人才、政策法规、安全等8个方面，旨在系统构建人工智能基础支撑体系，推动人工智能与经济社会各 领域各行业广泛深度融合，探索形成中国特色人工智能发展路径。 21世纪经济报道记者注意到，2024年，"人工智能+"首次被写入政府工作报告。今年政府工作报告又提 出，持续推进"人工智能+"行动。中央持续部署下，全国多地关于"人工智能+"的行动方案接连出炉，今 年以来，天津、安徽、四川、辽宁、宁夏等多地便规划了关于"人工智能+"的最新"行动路线"。此外 ...

Group 1 - The 15th China-Northeast Asia Expo concluded in Changchun, showcasing the deepening and broadening of cooperation among participating countries [1][2] - The expo is the only international comprehensive exhibition involving six Northeast Asian countries, promoting trade and investment cooperation in the region for 20 years [1] - A total of 20,733 guests from 45 countries and regions attended, including executives from 44 Fortune Global 500 companies, indicating a rising level of international participation [1] Group 2 - The expo emphasized the concept of "exhibition promotes trade, conference promotes investment," focusing on industry and project matching, and facilitating economic and cultural exchanges [2] - A total of 34 main and thematic activities were held, creating a multi-level and wide-ranging communication mechanism [2] - Successful events included the Russia Business Day and China-Japan Economic and Trade Exchange, enhancing cooperation in sectors like hydrogen energy [2]

Core Insights - The Fourth China (Macau) International High-Quality Consumption Expo and Hengqin World Bay Area Forum will be held from September 3 to 7, showcasing a focus on the health and wellness industry, particularly traditional Chinese medicine [1][4] - The expo aims to create an international health and wellness exhibition area, featuring advanced medical devices, health technology products, and health supplements, integrating both traditional Chinese and modern Western medicine [1][4] Industry Developments - The event will include a sub-forum titled "Healthy New Ecology Bay Area Together for the Future," where government officials and industry experts will discuss the collaboration results between Guangdong and Macau in the health industry [1][4] - The expo reflects the rapid development of the Greater Bay Area's industry and the acceleration of the trillion-level health consumption market [4] Economic Data - According to the National Bureau of Statistics, from 2014 to 2024, per capita medical care spending in China is projected to increase from 1,045 yuan to 2,547 yuan, with the share of medical care spending in total consumption rising from 7.2% to 9.0% [4] - It is predicted that by 2030, the total scale of China's health service industry will reach 16 trillion yuan [4]

Group 1 - The company plans to distribute a cash dividend of 0.1966 yuan per 10 shares, totaling approximately 29.41 million yuan, based on a total share capital of 1,495,879,748 shares as of June 30, 2025 [1][35][36] - The company will not implement a capital reserve transfer to increase share capital for the first half of 2025 [1][36] - The board of directors and the supervisory board have confirmed the authenticity, accuracy, and completeness of the half-year report [3][20] Group 2 - The board meeting held on August 27, 2025, approved the half-year report and the profit distribution plan [8][39] - The supervisory board also reviewed and approved the half-year report and the profit distribution plan, confirming compliance with legal and regulatory requirements [25][29] - The company has ensured that the profit distribution plan considers profit realization, cash flow status, and funding needs [39][41]

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于中国医药健康产业股份有限公司 致：中国医药健康产业股份有限公司 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件 和材料，保证本法律意见书不存在虚假、误导性陈述及重大遗漏，并对本法律意 见书的真实性、准确性、完整性承担相应的法律责任。 在本法律意见书中，本所根据本法律意见书出具日或以前发生的事实及本所 律师对该事实的了解，仅就本次股东大会的程序事宜所涉及的相关法律问题发表 法律意见。本所同意公司将本法律意见书作为本次股东大会的必需文件公告，并 依法对所出具之法律意见承担责任。本法律意见书仅供公司为本次股东大会之目 的而使用，不得被任何人用于其他任何目的。 除本法律意见书特别说明外，若相关数据合计数与各分项数值之和不等于 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标准、 道德规范及勤勉尽责精神，对公司提供的相关文件和有关事实进行了核查和验证， 现出具法律意见如下： 一． 本次股东大会的召集、召开程 ...

Core Viewpoint - The strategic cooperation between Tsinghua Holdings Northeast Headquarters and Changchun Economic Development Zone aims to enhance collaboration in the fields of pharmaceutical health, optoelectronic information, international cooperation, and industrial incubation over the next decade [1] Group 1: Strategic Cooperation - The signing ceremony signifies a commitment to deep collaboration in various sectors [1] - The partnership will focus on high-quality development of the "Northern Eye Valley" as a primary task [1] - National key projects will serve as a guiding force for the collaboration [1] Group 2: Industry Development - The initiative aims to build a multi-level pharmaceutical health industry platform [1] - The development will be driven by the innovative scene demands of the Changchun Economic Development Zone [1] - The goal is to promote the integration of technology and industry [1]

Core Viewpoint - The company reported a significant decline in revenue for the first half of 2025, with total operating income decreasing by 30.68% compared to the same period in the previous year, primarily due to structural adjustments in the consumer industry and fluctuations in international gold prices [1][2][3]. Summary by Category Business Performance - The total operating income for the first half of 2025 was approximately 19.11 billion yuan, down from 27.57 billion yuan in the same period last year [2][3]. - The gross profit margin decreased by 32.11% year-on-year, indicating a challenging operating environment [2][3]. - The jewelry segment saw a slight increase in gross profit margin by 0.43%, while the restaurant management and services segment experienced a decrease of 0.74% [1][2]. Revenue Breakdown by Industry - The main business segments included: - Jewelry: Revenue of approximately 14.54 billion yuan, with a gross profit margin decrease of 35.87% [1]. - Food and Beverage: Revenue of approximately 510.89 million yuan, with a gross profit margin decrease of 16.69% [1]. - Other segments, such as pharmaceuticals and cosmetics, also reported varying changes in revenue and gross profit margins [1][2]. Revenue Breakdown by Region - Revenue by region showed significant variances: - Shanghai: Revenue decreased by 40.70% to approximately 14.08 billion yuan [3]. - Sichuan: Revenue increased by 121.59% to approximately 535.18 million yuan [3]. - Notable declines were observed in regions like Japan, where revenue fell by 61.75% [3]. - The overall regional performance reflects a mixed impact of market conditions and operational adjustments [3]. Store Network - As of June 2025, the company operated a total of 4,249 retail outlets under the "Lao Miao" and "Ya Yi" brands, down from 4,615 at the end of 2024 [4]. - The company continues to adjust its store network based on regional market conditions, indicating a strategic response to changing consumer behaviors [4].